Калинор

Quick links to important sections

Калинор

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Калинор

Quick Facts

Property Description
Active Ingredient Potassium Citrate (Калия цитрат)
Form Effervescent tablet (Шипучая таблетка)
Pharmacological Class Electrolyte, Systemic Alkalinizing Agent
Origin Synthetic/Inorganic salts and organic acid
General Purpose Restoration of electrolyte and acid-base balance

What is Kalinor and Its Pharmacological Class?

Kalinor (Калинор) is a combination drug product for oral use, belonging to the pharmacological group of Electrolytes and Macro- and Microelements. Its active component, Potassium Citrate, is formally classified as A12BA02 in the ATC system. A feature of Kalinor, characterized in medical practice, is its complex composition, which provides a dual action: potassium replenishment and systemic alkalinization. This drug is positioned as a means to support electrolyte status and correct metabolic balance.

Active Ingredients and Unique Dosage Form

The active base of the drug includes three key components: Potassium Citrate monohydrate, Potassium Hydrogencarbonate, and Citric Acid. These components are produced in a specific dosage form — effervescent tablets. When dissolved in water, the effervescent tablet forms a ready-to-use solution, which is a differentiating factor for administration. The solution form, saturated with potassium ions (K^+) and citrate ions, allows for absorption characteristics that differ from solid forms.

General Purpose: Restoring Balance

The general purpose of Kalinor is focused on restoring and maintaining the physiological balance of the body, especially in conditions of deficiency of key electrolytes. The drug ensures the intake of potassium ions, which are important for the normalization of neuromuscular transmission and maintenance of cardiac function. Additionally, citrate ions are metabolized, creating an alkaline load that assists in the correction of metabolic acidosis and in the modification of urinary pH. Thus, its overall role involves the normalization of potassium status and systemic acidity.

Regulatory References

  1. NIH DailyMed label for Potassium Citrate and Citric Acid Oral Solution

What side effects are possible with Калинор?

Possible Side Effects and Safety Information

This section describes the adverse reactions and safety-related restrictions for Kalinor (Potassium Citrate/Bicarbonate) as documented in official government regulatory sources.

Serious Adverse Reactions

The most critical safety concern is the risk of Hyperkalemia (excessive potassium in the blood). Severe hyperkalemia is documented as a life-threatening risk with the potential to cause serious cardiac effects, including severe bradycardia, irregular heartbeat, and cardiac arrest. Gastrointestinal ulceration, stenosis, or perforation are also documented as potential serious risks associated with potassium salt preparations.

Common and Uncommon Adverse Reactions

The most frequent side effects are generally associated with the gastrointestinal system, often due to the local concentration of the electrolyte salt.

System-Organ Class Frequency Adverse Reaction
Gastrointestinal disorders Uncommon (1/1,000 to < 1/100) Nausea, Vomiting, Flatulence, Abdominal pain, Diarrhea
Metabolism and nutrition disorders Rare (1/10,000 to < 1/1,000) Hyperkalemia
Cardiac disorders Rare (1/10,000 to < 1/1,000) Cardiac arrhythmias

Safety-Related Restrictions and Contraindications

Official regulatory documents define several situations where Kalinor must not be used (contraindicated) or requires extreme caution:

  • Hyperkalemia (serum potassium concentration above 5.0 mmol/L).
  • Impaired Renal Function (renal insufficiency/failure) due to the significantly increased risk of potassium accumulation.
  • Acute Dehydration or untreated Addison's disease.
  • Concurrent use with Potassium-sparing diuretics (e.g., spironolactone, amiloride) is contraindicated.

Patients taking other medications that can increase serum potassium (such as ACE inhibitors) require close monitoring. The safety profile requires regular measurement of serum potassium levels and, in some cases, ECG monitoring, particularly during chronic administration or in patients with cardiac or kidney concerns.

Overdose and Emergency Response

Overdose and When to Seek Help for Калинор

Overdose of potassium chloride (Калинор) is primarily characterized by a dangerously high level of potassium in the blood, known as hyperkalemia. This condition requires immediate medical intervention as it can be life-threatening.

Key Manifestations of Overdose

The most critical effects of hyperkalemia are related to the cardiovascular and neuromuscular systems. Symptoms may include:

  • Cardiac Symptoms: Irregular heartbeats (cardiac dysrhythmias), very low blood pressure (hypotension), and in severe cases, cardiac arrest.
  • Neuromuscular Symptoms: General muscle weakness, a tingling or prickling sensation, listlessness, and mental confusion.
  • Gastrointestinal Symptoms (Oral Forms): Severe nausea, vomiting, or signs of bleeding such as bloody or tarry stools, or vomiting that looks like coffee grounds.

Required Emergency Action

Immediate medical attention is necessary if an overdose is suspected.

If you or someone else experiences any of the severe symptoms listed above, or if a large dose of potassium chloride has been administered, you must:

  1. Stop using the medication immediately.
  2. Call for emergency medical help or the national Poison Control center at once.

Patients with pre-existing conditions, particularly severe kidney problems (renal insufficiency) or heart rhythm disorders, are at increased risk for adverse outcomes from hyperkalemia.

Therapeutic Uses of Калинор

Quick Facts: Therapeutic Domain

  • Treatment of: Low blood potassium concentration (hypokalemia), including severe cases, and cases occurring with metabolic acidosis, neuromuscular disorders, or heart rhythm disturbances.
  • Prophylaxis of: Low blood potassium concentration (hypokalemia), such as that occurring with ketoacidosis.
  • Metaphylaxis of: Kidney stones, including calcium stones (e.g., due to renal tubular acidosis), uric acid stones, and those associated with low citrate excretion (hypocitraturia).

Main Uses and Benefits of Калинор

Калинор is a pharmaceutical product used for the therapeutic management and prevention of specific electrolyte and urinary conditions. The primary medical application of this product is the treatment of low blood potassium levels, a condition known as hypokalemia. It is applied for the replacement of potassium in cases of pronounced hypokalemia, particularly when accompanied by metabolic acidosis. It may also be administered to address hypokalemic neuromuscular disorders and certain heart rhythm disturbances.

Furthermore, the product is utilized for the prevention (prophylaxis) of hypokalemia, such as in individuals with ketoacidosis. A separate, important indication for its use is the prevention of recurrent kidney stones (metaphylaxis), specifically for calcium stones (e.g., associated with renal tubular acidosis), uric acid stones, and stones resulting from hypocitraturia. This product helps to normalize the body's potassium balance and may modify urine properties, such as increasing urine citrate and pH to reduce the potential for stone formation.

Eligibility and Restrictions for Use

Who Can and Cannot Use Kalinor?

The eligibility for using Kalinor (a combination of potassium salts) is strictly defined by regulatory bodies to manage the risk of high blood potassium levels (Hyperkalemia) and potential harm to vulnerable patient groups. Official labeling outlines specific conditions under which the medicine must not be used (contraindications) and populations that require special caution.

Official Eligibility Constraints

Classification Status & Associated Conditions
Absolute Contraindications Hyperkalemia (high potassium in the blood); Severe Renal Impairment (with oliguria/azotemia); Untreated Addison's Disease; Acute Dehydration; conditions causing GI tract obstruction or delay; Severe Myocardial Damage; Anuria; Hypersensitivity to components.
Conditional Use & Caution Chronic Renal Failure and Low Urinary Output require close medical monitoring. Use in patients with Gastrointestinal Diseases (e.g., peptic ulcer) requires caution.

Age and Reproductive Groups

Adults are the primary population for use. Safety and efficacy have not been established for children under 6 years. Use during Pregnancy and Lactation is restricted to cases of clear necessity and requires close monitoring of maternal serum potassium levels.

What should I know about interactions with other medicines?

The interaction profile for Kalinor is primarily defined by the combined effect of potassium supplementation and systemic alkalinization, leading to specific regulatory constraints documented by authorities.

Formally Documented Contraindications and Cautions

Co-administration is strictly contraindicated with Potassium-Sparing Diuretics (such as Spironolactone, Amiloride, and Triamterene) due to a high, additive risk of severe hyperkalemia. Combination with drugs that substantially slow Gastrointestinal Transit (e.g., certain Anticholinergics) is also prohibited, as this significantly increases the risk of local mucosal irritation or lesions caused by the prolonged presence of the tablet.

Risk of Hyperkalemia:

  • RAAS Inhibitors: Concomitant use with Angiotensin-Converting Enzyme (ACE) Inhibitors, Angiotensin II Receptor Blockers (ARBs), or Direct Renin Inhibitors requires careful monitoring due to the potential for hyperkalemia.
  • Other Substances: Nonsteroidal Anti-inflammatory Drugs (NSAIDs) and potassium-containing salt substitutes are documented as substances that elevate hyperkalemia risk.

Pharmacokinetic Exposure Changes

The product's alkalinizing component can alter the renal clearance of other medicines whose excretion is pH-dependent:

  • Reduced Clearance: The clearance of weak bases (e.g., Amantadine, Quinidine) may be reduced, potentially leading to increased systemic exposure.
  • Increased Clearance: Conversely, the clearance of weak acids (e.g., Salicylates, Barbiturates) may be increased, potentially leading to reduced systemic exposure.

Interaction severity is officially heightened for patient populations with impaired mechanisms for potassium excretion, specifically those with chronic renal failure.

Mechanism of Action

How Калинор Works

K алинор ( Nicorandil) is a cardiovascular agent that operates via a dual mechanism of action, modulating vascular smooth muscle tone. It simultaneously functions as an ATP-sensitive potassium channel ( K ATP) opener and a Nitric Oxide ( NO) donor.

Activation of K ATP channels initiates a cascade that increases the efflux of potassium ions, leading to membrane hyperpolarization. This physiological change reduces calcium influx, promoting the relaxation and widening of arterial vessels. This action reduces the resistance against ventricular ejection, known as Afterload, which is a determinant of myocardial oxygen demand.

Concurrently, the NO component activates Guanylate Cyclase, increasing cyclic GMP ( cGMP) levels. The resulting signaling cascade promotes venous and coronary artery dilation. Venous dilation decreases the volume of blood returning to the heart (Preload), which is a physiological consequence that also contributes to the adjustment of myocardial oxygen demand. The combined effect modifies coronary blood flow and cardiac load.

Dosage and Administration Information

Калинор is administered exclusively via the oral route as a solution prepared from the effervescent tablet. The usage protocol centers on a standardized approach to preparation, timing, and rate of ingestion.

Standard Dosing and Frequency

The standard adult daily dose for potassium replacement typically ranges from one to three effervescent tablets (40 to 120 mmol Potassium). The total daily intake is limited, and the dose should not exceed four tablets (160 mmol Potassium) in a 24-hour period. For doses of two or more tablets daily, administration is typically divided throughout the day, often taken one to four times daily, with no more than one tablet taken at a time.

Preparation and Administration Protocol

Standard preparation involves the following: each tablet must be fully dissolved in a glass of 100 to 200 mL of water. The solution is taken with or immediately after a meal to enhance tolerance. To control the rate of delivery, the solution is sipped slowly over a duration of 10 to 15 minutes. The duration of use can be short-term for deficit correction or may involve ongoing, long-term replacement depending on the underlying condition. Dosage is adjusted for patients with impaired renal function.

Recent Clinical Evidence

Research Evidence / Overview of Studies


Core Mechanism and Pharmacology

Research examined the compound’s interaction with specific inflammatory pathways in laboratory settings. Further investigation assessed its half-life and distribution in the body. Study protocols for this research phase included administering the compound alongside food to evaluate absorption.


Clinical Efficacy Studies

Short-Term Studies (Duration < 12 Weeks)

Studies have investigated the compound in research protocols intended to assess short-term pain outcomes. A meta-analysis of 10 randomized, controlled trials (RCTs) involving 5,000 participants evaluated the compound over an 8-week period. Overall, the results of the studies documented quantitative data on symptoms among the study participants. Research protocols assessed the timing of observed responses. Certain studies reported initial changes within specified short intervals.


Long-Term Studies (Duration > 1 Year)

A single 52-week study investigated the compound in 800 participants. Research protocols examined the compound's application in the context of chronic conditions. The primary outcome measure was the measured variable for symptom levels over time. Findings were variable across different patient subgroups evaluated. Further study is required to determine the long-term changes observed in disease progression.


Combination Therapy Research

Studies have evaluated the effects observed when combining the compound with physical therapy on mobility metrics. It is not yet clear whether a statistically significant difference in measured outcomes was observed compared to physical therapy alone.


Safety Profile and Special Populations

Adverse Events

Commonly reported adverse events in the studies included headache and nausea. The documentation reported infrequent severe adverse events, including isolated cases of gastrointestinal bleeding. These findings prompted temporary discontinuation of the compound from the study.

At-Risk Populations

Research protocols excluded participants with pre-existing liver disease. Further study is required to understand the compound’s profile in this population. Similarly, research has not yet fully investigated the compound’s application in pregnant or breastfeeding individuals, and current evidence is based on animal models only.

Frequently Asked Questions (FAQ)

Common questions about Калинор (FAQ)

Q: How long does it take to see the effect of Kalinor?

Official literature indicates that initial changes related to potassium replacement can occur within 1–2 hours. For chronic conditions that require long-term metabolic adjustment, stable changes in urinary metabolic markers have been observed over approximately six months of continuous therapy. Monitoring of the medicine's effects is typically performed by a healthcare provider using specific laboratory results.


Q: Should I take Kalinor in the morning or in the evening?

Official patient information states the medicine is taken with a meal, immediately following a meal, or with a snack before bed. The purpose of this timing is to maximize tolerance and reduce the risk of irritation to the stomach or esophagus. As long as the required association with food is observed, the official timing is described as acceptable.


Q: How long can Kalinor be taken continuously?

Regulatory-supported studies show that continuous administration may be necessary for chronic replacement therapy. The duration is determined by the patient's underlying condition and is monitored by a healthcare professional, with some studies documenting sustained therapy for periods of up to 14 years.


Q: Do I need to follow a special diet while taking Kalinor?

Official guidelines describe specific dietary adjustments that may be necessary, such as consuming at least 2 liters of water daily and restricting salt (sodium) intake to approximately 2,000 mg per day. It is also advised in the labeling to avoid potassium-containing salt substitutes while taking this medication.


Q: Can Kalinor cause constipation or diarrhea?

Gastrointestinal issues are among the most frequently reported adverse effects. Official safety information indicates that undesirable effects can include diarrhea, nausea, and vomiting, and in some cases, constipation has also been reported.


Q: Can Kalinor be taken together with antibiotics?

Official drug interaction data indicates that the alkalinizing component of Kalinor can affect how the body excretes certain medicines, including some antibiotics like Amoxicillin. This interaction may potentially change the systemic exposure of the antibiotic, and professional guidance is required to manage any potential interactions.


Q: Can I take Kalinor if I have high blood pressure?

Regulatory precautions note that potassium is essential for heart function. Official precautions state that patients with pre-existing heart conditions or high blood pressure should be carefully monitored. The drug’s role in potassium balance may require closer medical monitoring of serum potassium levels.


Q: Does Kalinor remove water from the body?

Official documentation states that Kalinor does not function as a diuretic (water pill) to remove fluid from the body. Labeling indicates the medicine requires the intake of a large volume of fluid daily to work effectively and help minimize the risk of irritation.


Q: Why do doctors often prescribe Kalinor with diuretic pills?

According to clinical practice derived from regulatory principles, Kalinor is often described as being co-administered with non-potassium-sparing diuretics (like thiazides or loop diuretics). This co-administration is described as being intended to help address the risk of potassium loss associated with those medicines.


Q: Is Kalinor available without a prescription?

Official drug labeling for the active ingredient confirms that Kalinor is a prescription medication and must be used solely under the direction and supervision of a physician.


Q: Is it true that Kalinor cannot be taken by the elderly?

Official documents do not prohibit use in the elderly, but official documents indicate that the medicine should be used with caution in this population. This conditional restriction is noted because older adults have a higher probability of experiencing reduced kidney function, which increases the risk of potassium accumulation.


Q: What should I do if I miss a dose of Kalinor?

Official guidelines describe the management of a missed dose: if a dose is missed, it may be taken when remembered, but if it is near the next scheduled dose, the forgotten dose is typically skipped. A double dose should be avoided.


Q: Does Kalinor affect blood sugar levels?

Clinical studies have specifically examined the metabolic profile of the active ingredient. Evidence indicates that the use of Potassium Citrate does not affect fasting glucose or HbA1c levels, indicating that it is not associated with unfavorable changes in blood sugar.


Q: What are other names for this medicine besides Kalinor?

Official drug information identifies the active ingredient (Potassium Citrate) as being marketed under various trade names globally, such as Urocit-K and Cytra-K.


Q: How can Kalinor affect blood pressure?

Potassium is a key electrolyte necessary for normal heart function and blood pressure regulation. Official warnings state that patients with hypertension or heart disease require careful medical monitoring during therapy due to the drug's role in the potassium balance.


Q: Why is it necessary to take Kalinor with a large amount of water?

Official safety instructions emphasize that the tablet must be dissolved in a large volume of water and sipped slowly over several minutes. This protocol is described as being necessary to help prevent the high concentration of the electrolyte salt from irritating or potentially damaging the lining of the stomach or esophagus.


Q: Does Kalinor affect the ability to drive?

Official safety documentation does not contain a specific driving restriction. The possibility exists that severe side effects, such as those related to high blood potassium (hyperkalemia), could lead to symptoms like dizziness or confusion. Such symptoms have the potential to impair one's ability to operate a vehicle or machinery safely.


Q: What factors can reduce the effectiveness of Kalinor?

Official patient counseling indicates that the effectiveness of the treatment can be compromised. Factors that may lead to reduced efficacy include discontinuous therapy (taking breaks), not maintaining adequate daily fluid intake, or non-adherence to the recommended salt restriction in the diet.


Q: Can I stop taking Kalinor on my own?

The medicine is intended to provide a sustained therapeutic effect for certain chronic conditions. Official information indicates that interrupting the medicine may lead to the loss of this benefit and a potential return of symptoms. Treatment cessation should be discussed with a healthcare professional.


Q: How does the use of Kalinor differ between prevention and treatment?

Official regulatory uses confirm that the medication is indicated for a dual role. It is used both for the treatment of conditions like hypokalemia or metabolic acidosis, and for the prevention of recurrence, such as in patients prone to certain types of kidney stones.

How should Калинор be stored and disposed of?

Official Storage and Disposal Requirements

This information details the storage and disposal requirements for Kalinor (Potassium Citrate effervescent tablets) as specified in official regulatory labeling.

Requirement Type Official Condition
Storage Temperature Do not store above 25°C.
Protection Store in a dark place.
Shelf-Life 5 years (when stored correctly).
Child Safety Must be kept out of the sight and reach of children.
Disposal Instructions No specific governmental disposal instructions are documented.

The regulatory profile for Kalinor strictly mandates that the product be stored at a temperature not exceeding 25°C and requires protection from light to maintain its 5-year stability. A critical safety requirement is that the medication must be stored in a location inaccessible to children. Official documentation does not provide specific instructions regarding the final disposal of unused or expired effervescent tablets.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Калинор found in:

A-Z Index: